COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.

Détails

ID Serval
serval:BIB_B43AB2221524
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
Périodique
Multiple sclerosis
Auteur⸱e⸱s
Jeantin L., Januel E., Labauge P., Maillart E., de Seze J., Zéphir H., Pelletier J., Kerschen P., Biotti D., Heinzlef O., Guilloton L., Bensa C., Théaudin M., Vukusic S., Casez O., Maurousset A., Laplaud D., Berger E., Lebrun-Frenay C., Bourre B., Branger P., Stankoff B., Clavelou P., Thouvenot E., Manchon E., Moreau T., Sellal F., Zedet M., Papeix C., Louapre C.
ISSN
1477-0970 (Electronic)
ISSN-L
1352-4585
Statut éditorial
Publié
Date de publication
03/2024
Peer-reviewed
Oui
Volume
30
Numéro
3
Pages
381-395
Langue
anglais
Notes
Publication types: Observational Study ; Multicenter Study ; Journal Article
Publication Status: ppublish
Résumé
Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021.
We aimed to extend these data from the onset of the pandemic to the global coverage by vaccination in summer 2022.
This retrospective, multicenter observational study analyzed COVISEP registry data on reported COVID-19 cases in pwMS between January 2020 and July 2022. Severe COVID-19 was defined as hospitalization or higher severity.
Among 2584 pwMS with confirmed/highly suspected COVID-19, severe infection rates declined from 14.6% preomicron wave to 5.7% during omicron wave (p < 0.001). Multivariate analysis identified age (odds ratio (OR) = 1.43, 95% confidence interval (CI) = [1.25-1.64] per 10 years), male sex (OR = 2.01, 95% CI = [1.51-2.67]), obesity (OR = 2.36, 95% CI = [1.52-3.68]), cardiac comorbidities (OR = 2.36, 95% CI = [1.46-3.83]), higher Expanded Disability Status Scale (EDSS) scores (OR = 2.09, 95% CI = [1.43-3.06] for EDSS 3-5.5 and OR = 4.53, 95% CI = [3.04-6.75] for EDSS ⩾6), and anti-CD20 therapies (OR = 2.67, 95% CI = [1.85-3.87]) as risk factors for COVID-19 severity. Vaccinated individuals experienced less severe COVID-19, whether on (risk ratio (RR) = 0.64, 95% CI = [0.60-0.69]) or off (RR = 0.32, 95% CI = [0.30-0.33]) anti-CD20.
In pwMS, consistent risk factors were anti-CD20 therapies and neurological disability, emerging as vital drivers of COVID-19 severity regardless of wave, period, or vaccination status.
Mots-clé
Humans, Male, Child, COVID-19, Multiple Sclerosis, Retrospective Studies, Heart, Hospitalization, COVID-19 testing, COVID-19 vaccines, Multiple sclerosis, SARS-CoV-2, vaccination
Pubmed
Web of science
Création de la notice
26/01/2024 12:31
Dernière modification de la notice
26/03/2024 8:10
Données d'usage